6 edition of Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development) found in the catalog.
April 2000 by Humana Press .
Written in English
|Contributions||Lloyd R. Kelland (Editor), Nicholas P. Farrell (Editor)|
|The Physical Object|
|Number of Pages||360|
Nature of France.
The 2009-2014 world outlook for fossil fuel-powered electric power generation
At the zoo
Getting down to brass tacks
Your first budgerigar
Cook Islands Culture Akonoanga Maori
Atmospheric turbulence relative to aviation, missile, and space programs
Wortabets Arabic-English dictionary.
An ambassadors memoirs.
List of documents belonging to the Right Hon. the Earl of Aylesford at Packington Hall
The Platinum-based Drugs in Cancer Therapy appears to be a comprehensive book useful for scientist, medical oncologist and pharmacist seeking answer on specific questions concerning preclinical and clinical data of platinum drugs."-Neoplasma "The strength of the text lies in the diversity of topics that are covered in such a succinct fashion.
The Platinum-based Drugs in Cancer Therapy appears to be a comprehensive book useful for scientist, medical oncologist and pharmacist seeking answer on specific questions concerning preclinical and clinical data of platinum drugs."-Neoplasma5/5(1).
Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development): Medicine & Health Science Books @ 5/5(1). Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.
Platinum-Based Drugs in Cancer Therapy by Lloyd R. Kelland,available at Book Depository with free delivery worldwide.5/5(1). Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new : Humana Press.
COVID Resources. Platinum-Based Drugs in Cancer Therapy book Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle.
Leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use Platinum-Based Drugs in Cancer Therapy book treatment, as well as examining their future therapeutic prospects.
Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous Price: $ Platinum Therapy is the use of platinum compounds, which are cell damaging agents, for the treatment of specific cancers, including testicular, ovarian, lung, bladder, and head and neck cancers.
Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis).Platinum compounds currently used are cisplatin, carboplatin and oxaliplatin.
Get this from a library. Platinum-based drugs in cancer therapy. [Nicholas Farrell; Lloyd R Kelland;] -- In Platinum-Based Drugs in Cancer Therapy, leading Platinum-Based Drugs in Cancer Therapy book experts comprehensively review all Platinum-Based Drugs in Cancer Therapy book of platinum anticancer drugs and their current use in treatment, as well as examining their.
Platinum-based drugs have become a mainstay of cancer therapy; approximately half of all patients undergoing chemotherapeutic treatment receive a platinum drug ().The widespread use of platinum agents in the treatment of cancer began with the discovery of the antineoplastic activity of cisplatin by Barnett Rosenberg in the s ().Despite the pervasiveness of Cited by: Fink D, Howell S.
(eds) How does cisplatin kill cells Platinum-Based Drugs in Cancer Therapy Totowa, NJ: Humana Press Inc; –Kelland L, Farrell N (eds) Fossella FV. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials Semin Oncol a 26 17, 41–discussion ; Fossella by: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms.
Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Much effort has been put into the development of new platinum Platinum-Based Drugs in Cancer Therapy book complexes, but none of them has reached worldwide Cited by: Platinum-based Drugs.
Platinum-based drugs are used to treat ovarian cancer, testicular cancer, and colon cancer. They work by by slowing down the growth of cancer cells and killing them.
Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs.
This important book captures the essence of the fresh clinical possibilities now strongly emerging thirty. The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose.
1. Platinum-based cancer treatment 2. Overview Platinum based therapy refers to a specific class chemotherapy drugs that are derived from the element platinum.
There are three major platinum based cancer treatment drugs These drugs are used to treat advanced forms of a variety of cancers including colon, lung, ovarian, head and neck cancers. Roughly 10 to 20 percent of all cancer patients get a prescription for a platinum-based drug, according to the National Cancer Institute.
Doctors use platinum drugs to treat many kinds of cancer Author: Carmen Drahl. The discovery and development of new platinum-containing anticancer drugs have represented an integral part of anticancer drug development at. Buy Platinum-Based Drugs in Cancer Therapy by Lloyd R.
Kelland, Nicholas P. Farrell from Waterstones today. Click and Collect from your local Waterstones or get FREE UK delivery on orders over £Book Edition: Ed. Platinum-based agents with respect to their structure, mechanism of action and strategies developed for improved efficacy in cancer treatment have been summarized in this paper with the perspective of developing new platinum drugs or platinum-based therapy for.
Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents) as part of a standardized chemotherapy herapy may be given with a curative intent (which almost always involves combinations of drugs), or it may aim to prolong life or to reduce Other names: chemo.
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
Platinum-based drugs continue being the support of therapy for many different kinds of cancer. Cancer patients often present irreversible resistance to platinum after repeated treatment in clinic. Despite of the great efforts, chemoresistance (intrinsic or acquired) already is a major limitation in the management of this disease.
In this review, the last current research on cancer. Platinum-based chemotherapy regimens did not offer a statistically significant benefit in survival or overall tumour response compared with non-platinum-based regimens.
However, platinum-based chemotherapy regimens did increase complete response rates, at the cost of higher adverse events including nausea and vomiting, anaemia and thrombocytopenia. The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose-limiting side effects (also referred to as adverse effects/events).
In total, a cancer patient can experience any combin Frontier and Perspective articlesCited by: Platinum compounds are one of the most widely used classes of agents in cancer therapy; however, platinum drugs approved for clinical use are rarely given to patients as a monotherapy.
A concept that is emerging is the utilization of a biological messenger to abrogate the development of resistance. Landier W. Ototoxicity and cancer therapy. Cancer ; Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
Maintenance Therapy for Ovarian Cancer. First-line therapy with a combination of surgery and platinum-based chemotherapy is the standard of care for women who are newly diagnosed with advanced ovarian cancer. For most women, however, the cancer returns within 3 years of this initial treatment.
The matched sample comprised ovarian cancer patients ( each in platinum-based chemotherapy and nonplatinum/no chemotherapy group). Patients were then hierarchically grouped into four categories: no chemotherapy, other nonplatinum chemotherapy, only platinum-based chemotherapy, and platinum plus taxane by: 8.
Although SAL analogs showed less promising IC 50 values than SAL, they were identified as the antitumor agents that significantly overcome the resistance to platinum-based drugs in ovarian cancer, more potent than unmodified SAL and commonly used anticancer drugs—5-fluorouracil, gemcitabine, and cisplatin.
Moreover, when compared with SAL Author: Marcin Michalak, Michał Stefan Lach, Michał Antoszczak, Adam Huczyński, Wiktoria Maria Suchorska. The industry is primarily driven by a rising prevalence of various cancers among the world population and the growing prominence of platinum based drugs in cancer therapy.
Fred Hutchinson Cancer Research Center. (, February 11). Why Certain Ovarian Cancers Develop Resistance To Platinum-based Chemotherapy. ScienceDaily. Retrieved May 2, from www. These drugs are used either alone or in combination with other drug treatment.
Rise in prevalence of cancer is a major driver of the global platinum-based drugs market. According to the National Cancer Institute, the number of new cancer cases per year is expected to /5(34). Chemo-resistance of breast cancer is a major obstacle for successful treatment and is mainly represented as a defect in apoptosis.
The differential effects of platinum-based drugs (PBDs) were assessed on breast cancer cell ultrastructure. Three representative cells, including triple-negative breast cancer (TNBC), were treated with different concentrations and timings of Author: Shadia Al-Bahlani, Samiya Al-Jaaidi.
Enhancing The Effects Of Platinum-based Anti-cancer Drugs Date: June 2, Source: Journal of Clinical Investigation Summary: Researchers have now identified a way to enhance the in vitro. Why cancer drugs lose their power: Platinum-based cancer drugs destroy tumor cells by binding to DNA strands.
by Anne Trafton, Massachusetts Institute of Technology. Notes: The second generation of platinum cancer drugs. Designed to have less severe side effects. Used for many of the same cancers and in similar regimens to cisplatin.
Approved by the FDA in for o varian cancer. Oxaliplatin. Brand/Trade Names: Eloxatin, [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O’)platinum(II) Formula: C 8 H On Februthe Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca Inc.) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has.
The main strength of the current study is that it has been carried out at all. BRCA1 mutations account for a small proportion of patients with advanced breast cancer, even in countries with founder mutations, and this presents a substantial barrier to running studies testing standard chemotherapy.
Use of the chemotherapy regimen outside the trial, and the wide Cited by:. Pdf combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied platinum-based chemotherapeutics and drugs from a library composed of chemically and Cited by: 4.For use in combination download pdf radiation therapy (RT) for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) or as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed.
Imclone: Mar 01 chlorambucil: Leukeran.This subgroup comprised patients with metastatic SCLC, with disease progression after platinum-based therapy and at least one other prior line of .